Advertisement

Contemporary Treatment of Locally Advanced Oral Cancer

  • David Kim
  • Ryan LiEmail author
Head and Neck Cancer (CP Rodriguez, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Head and Neck Cancer

Opinion statement

At our institution, locally advanced oral cancer is most commonly treated with surgical resection, immediate reconstruction, and adjuvant radiotherapy with or without concurrent systemic therapy depending on final surgical pathologic analysis. There are patients with markedly advanced local or regional disease who unfortunately will have a low probability of cure. We counsel these patients on induction chemotherapy, emphasizing that this is unlikely to result in a smaller volume of surgical resection. In these patients, a good response to induction chemotherapy is more frequently followed by concurrent chemoradiotherapy. We have not been in the practice of commonly recommending definitive chemoradiotherapy for locally advanced oral cancer when upfront surgery is an option. However, as reviewed below, there is a significant rationale for definitive chemoradiotherapy in patients who are surgical candidates, with the hope of good oncologic outcomes, and potential functional organ preservation. The experts who report their experiences in the studies reviewed below provide a strong argument for considering this approach.

Keywords

Oral cavity squamous cell carcinoma Treatment Primary chemoradiotherapy Immunotherapy Neoadjuvant therapy Outcome 

Notes

Compliance with Ethical Standards

Conflict of Interest

David Kim and Ryan Li declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    AJCC 8th Edition. Springer International Publishing. American Joint Commission on Cancer; 2016.Google Scholar
  2. 2.
    Altice CK, Benegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Int. 2017;109(2).CrossRefGoogle Scholar
  3. 3.
    Massa ST, Rohde RL, McKinstry C, Gresham M, Osazuwa-Peters N, Ward GM, et al. An assessment of patient burdens from head and neck cancer survivorship care. Oral Oncol. 2018;82:115–21.CrossRefGoogle Scholar
  4. 4.
    Kumar M, Nanavati R, Tapan MG, Dobariya C. Oral cancer: etiology and risk factors: a review. Cancer Res Ther. 2015;12(2):458–63.CrossRefGoogle Scholar
  5. 5.
    Harris SL, Kimple RJ, Hayes DN, Couch ME, Rosenman JG. Never-smokers, never-drinkers: unique clinical subgroup of young patients with head and neck squamous cell cancers. Head Neck. 2010;32:499–503.PubMedGoogle Scholar
  6. 6.
    Lingen MW, Xiao W, Schmidt A, Jiang B, Pickard R, Kreinbrink P, et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 2013;49:1–8.CrossRefGoogle Scholar
  7. 7.
    D’Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, et al. Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med. 2015;373(6):521–9.CrossRefGoogle Scholar
  8. 8.
    •• Foster CC, Melotek JM, Brisson RJ, Seiwert TW, Cohen EEW, Stenson KM, et al. Definitive chemoradiation for locally-advanced oral cavity cancer: a 20-year experience. Oral Oncol. 2018;80:16–22. One of the largest retrospective studies summarizing a 20-year experience of primary chemoradiation for locally advanced oral cancer and demonstrating favorable survival outcomes and toxicity profiles.CrossRefGoogle Scholar
  9. 9.
    Myers JN, Greenberg JS, Bo V, Roberts D. Extracapsular spread. Cancer. 2001;92(12):3030–6.CrossRefGoogle Scholar
  10. 10.
    Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M. Differences in survival with surgery and postoperative radiotherapy compared with definitive chemoradiotherapy for oral cavity cancer: a national cancer database analysis. JAMA Otolaryngol Head Neck Surg. 2017;143(7):691–9.CrossRefGoogle Scholar
  11. 11.
    Gore SM, Crombie AK, Batstone MD, Clartk JR. Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma. Head Neck. 2015;37(4):518–23.CrossRefGoogle Scholar
  12. 12.
    Sher DJ, Thotakura V, Balboni TA, Norris CM Jr, Haddad RI, Posner MR, et al. Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011;81(4):e215–22.CrossRefGoogle Scholar
  13. 13.
    • Elbers JBW, Al-Mamgani A, Paping D, van den Brekel MWM, Jozwiak K, de Boer JP, et al. Definitive (chemo) radiotherapy is a curative alternative for standard of care in advanced stage squamous cell carcinoma. Oral Oncol. 2017;75:163–8. Large retrospective review reporting survival outcomes in patients with advanced oral cavity cancer treated with definitive chemoradiotherapy over a 13-year period.CrossRefGoogle Scholar
  14. 14.
    Crombie AK, Farah C, Tripcony L, Dickie G, Batstone MD. Primary chemoradiotherapy for oral cavity squamous cell carcinoma. Oral Oncol. 2012;48(1):1014–8.CrossRefGoogle Scholar
  15. 15.
    Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt MD, et al. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009;31(8):1013–21.CrossRefGoogle Scholar
  16. 16.
    Stenson KM, MacCracken E, List M, Haraf DJ, Brockstein B, Weichselbaum R, et al. Swallowing function in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2000;126(3):371–7.CrossRefGoogle Scholar
  17. 17.
    Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, et al. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010;120(1):93–9.PubMedGoogle Scholar
  18. 18.
    Owosho AA, Tsai CJ, Lee RS, Freymiller H, Kadempour A, Varthis S, et al. The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): the Memorial Sloan Kettering Cancer Center experience. Oral Oncol. 2017;64:44–51.CrossRefGoogle Scholar
  19. 19.
    Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685–90.CrossRefGoogle Scholar
  20. 20.
    Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, et al. Long-term update of the 24954 EORTC phase III trial on larynx preservation. Eur J Cancer. 2016;65:109–12.CrossRefGoogle Scholar
  21. 21.
    Soo KC, Tan EH, Wee J, Lim D, Tai BC, Khoo ML, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer. 2005;93(3):279–86.CrossRefGoogle Scholar
  22. 22.
    Iyer NG, Tan DS, Tan VK, Wang W, Hwang J, Tan NC, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599–607.CrossRefGoogle Scholar
  23. 23.
    Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–1.CrossRefGoogle Scholar
  24. 24.
    •• Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomized, open-label, phase 3 study. Lancet. 2018. Randomized phase 3 trial comparing pembrolizumab to standard chemotherapy drugs in recurrent or metastatic head and neck cancer, with pembrolizumab demonstrating prolonged overall survival with a favorable side effect profile.Google Scholar
  25. 25.
    Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119(2):153–9.CrossRefGoogle Scholar
  26. 26.
    Burtness B. First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): interim results from the phase 3 KEYNOTE-048 study. Presented at: European Society for Medical Oncology Congress; 2018 October 19–23, Munich, Germany.Google Scholar
  27. 27.
    Schwab KS, Kristiansen G, Schild HH, Held SEA, Heine A, Brossart P. Successful treatment of refractory squamous cell cancer of the head and neck with nivolumab and ipilimumab. Case Rep Oncol. 2018;11(1):17–20.CrossRefGoogle Scholar
  28. 28.
    Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Hong CS, et al. Long-term results of a randomized phase III TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget. 2015;6(21):18707–14.CrossRefGoogle Scholar
  29. 29.
    Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, et al. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol. 2014;25(2):462–6.CrossRefGoogle Scholar
  30. 30.
    Marta GN, Riera R, Bossi P, Zhong LP, Licitra L, Macedo CR, et al. Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: systematic review and meta-analysis. Eur J Cancer. 2015;51(17):2596–603.CrossRefGoogle Scholar
  31. 31.
    Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, et al. Biomarker and tumor responses of oral cavity squamous cell carcinoma to trametinib: a phase II neoadjuvant window-of-opportunity clinical trial. Clin Cancer Res. 2017;23(9):2186–94.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Otolaryngology-Head and Neck SurgeryOregon Health and Science UniversityPortlandUSA

Personalised recommendations